JP2018526403A - 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 - Google Patents

嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 Download PDF

Info

Publication number
JP2018526403A
JP2018526403A JP2018512407A JP2018512407A JP2018526403A JP 2018526403 A JP2018526403 A JP 2018526403A JP 2018512407 A JP2018512407 A JP 2018512407A JP 2018512407 A JP2018512407 A JP 2018512407A JP 2018526403 A JP2018526403 A JP 2018526403A
Authority
JP
Japan
Prior art keywords
antibody
formulation
patient
penetrating member
intestinal wall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018512407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526403A5 (enExample
Inventor
ミル イムラン，
ミル イムラン，
ラディカ コルポル，
ラディカ コルポル，
エレイン トー，
エレイン トー，
ジョエル ハリス，
ジョエル ハリス，
ミル ハシム，
ミル ハシム，
Original Assignee
インキューブ ラブズ， エルエルシー
インキューブ ラブズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/150,379 external-priority patent/US11548940B2/en
Application filed by インキューブ ラブズ， エルエルシー, インキューブ ラブズ， エルエルシー filed Critical インキューブ ラブズ， エルエルシー
Publication of JP2018526403A publication Critical patent/JP2018526403A/ja
Publication of JP2018526403A5 publication Critical patent/JP2018526403A5/ja
Priority to JP2021125408A priority Critical patent/JP2021169530A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018512407A 2015-09-08 2016-09-08 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 Withdrawn JP2018526403A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021125408A JP2021169530A (ja) 2015-09-08 2021-07-30 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562215586P 2015-09-08 2015-09-08
US62/215,586 2015-09-08
US15/150,379 US11548940B2 (en) 2014-05-15 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US15/150,379 2016-05-09
PCT/US2016/050832 WO2017044665A1 (en) 2015-09-08 2016-09-08 Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021125408A Division JP2021169530A (ja) 2015-09-08 2021-07-30 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤

Publications (2)

Publication Number Publication Date
JP2018526403A true JP2018526403A (ja) 2018-09-13
JP2018526403A5 JP2018526403A5 (enExample) 2019-10-03

Family

ID=58240088

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018512407A Withdrawn JP2018526403A (ja) 2015-09-08 2016-09-08 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤
JP2021125408A Pending JP2021169530A (ja) 2015-09-08 2021-07-30 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤
JP2023084891A Pending JP2023104992A (ja) 2015-09-08 2023-05-23 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021125408A Pending JP2021169530A (ja) 2015-09-08 2021-07-30 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤
JP2023084891A Pending JP2023104992A (ja) 2015-09-08 2023-05-23 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤

Country Status (7)

Country Link
EP (1) EP3347050B1 (enExample)
JP (3) JP2018526403A (enExample)
CN (1) CN108401419A (enExample)
AU (2) AU2016320867B2 (enExample)
CA (1) CA2997958A1 (enExample)
DK (1) DK3347050T3 (enExample)
WO (1) WO2017044665A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516513A (ja) * 2018-12-31 2022-02-28 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管の管腔への送達のための治療剤調製物
JP2022530615A (ja) * 2019-05-03 2022-06-30 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
KR102647155B1 (ko) 2017-05-17 2024-03-15 메사추세츠 인스티튜트 오브 테크놀로지 자가-직립 물품
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
CA3100710A1 (en) 2018-05-17 2019-11-21 Massachusetts Institute Of Technology Systems for electrical stimulation
US12128133B2 (en) 2018-09-25 2024-10-29 Rani Therapeutics, Llc Ingestible device with expandable enclosure
WO2020160399A1 (en) 2019-02-01 2020-08-06 Massachusetts Institute Of Technology Systems and methods for liquid injection
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515576A (ja) * 2009-12-24 2013-05-09 インキューブ ラブズ， エルエルシー 嚥下可能薬物送達デバイスおよび薬物送達方法
JP2014520812A (ja) * 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
JP2014520600A (ja) * 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 治療用化合物の経口送達のためのデバイス、システム、および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562589B2 (en) * 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
JP2013023499A (ja) * 2011-07-14 2013-02-04 Pfizer Inc 抗ｐｃｓｋ９抗体を用いた処置
CA2939507A1 (en) * 2014-02-14 2015-08-20 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
CN107835682A (zh) * 2015-05-08 2018-03-23 因库博实验室有限责任公司 使用可吞服药物递送装置递送至肠道内腔的抗白细胞介素抗体制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515576A (ja) * 2009-12-24 2013-05-09 インキューブ ラブズ， エルエルシー 嚥下可能薬物送達デバイスおよび薬物送達方法
JP2014520812A (ja) * 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
JP2014520600A (ja) * 2011-06-29 2014-08-25 ラニ セラピューティクス， エルエルシー 治療用化合物の経口送達のためのデバイス、システム、および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENCER B ET AL.: "PCSK9 inhibitors", SWISS MEDICAL WEEKLY, vol. 145, JPN6020028456, 9 April 2015 (2015-04-09), pages 14094, ISSN: 0004475655 *
小泉 直也: "ペプチド医薬品の経口投与製剤開発のための基礎検討", 上原記念生命科学財団研究報告集，［ONLINE］, vol. 第２７巻, JPN6020028459, 2013, ISSN: 0004475656 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516513A (ja) * 2018-12-31 2022-02-28 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管の管腔への送達のための治療剤調製物
JP2022530615A (ja) * 2019-05-03 2022-06-30 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物
JP7692363B2 (ja) 2019-05-03 2025-06-13 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物

Also Published As

Publication number Publication date
CA2997958A1 (en) 2017-03-16
CN108401419A (zh) 2018-08-14
AU2023204153A1 (en) 2023-07-20
EP3347050B1 (en) 2025-01-15
EP3347050A4 (en) 2019-05-22
JP2021169530A (ja) 2021-10-28
WO2017044665A1 (en) 2017-03-16
DK3347050T3 (da) 2025-04-14
AU2016320867A1 (en) 2018-04-05
AU2016320867B2 (en) 2023-03-30
EP3347050A1 (en) 2018-07-18
JP2023104992A (ja) 2023-07-28

Similar Documents

Publication Publication Date Title
US12018090B2 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7305008B2 (ja) 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
JP2023104992A (ja) 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤
US20230174639A1 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7232805B2 (ja) 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤
JP2022516513A (ja) 嚥下可能薬物送達デバイスを使用する腸管の管腔への送達のための治療剤調製物
US20230374155A1 (en) Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210810

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210811

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210824